Multiple Myeloma

CAR T-Cell Immunotherapy Named Advance of the Year in Annual ASCO Report

(ASCO) Jan 30, 2018 - Released today in advance of World Cancer Day, Clinical Cancer Advances 2018 highlights the most impactful clinical cancer research and policy developments over the past year.

read press release

Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy

(Yahoo! Finance) Jan 31, 2018 - The Multiple Myeloma Research Foundation, the world’s number one private funder of multiple myeloma research, and Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today highlighted the significant advancement of an innovative potential new treatment option, selinexor, Karyopharm’s lead, novel, oral Selective Inhibitor of Nuclear Export (SINE) compound, while part of the MMRF’s Biotech Investment Award (BIA) program.

read article

Celgene Corporation Announces Positive Results from the Pivotal Phase III ‘OPTIMISMM' Study of POMALYST/IMNOVID® for the Treatment of Relapsed or Refractory Multiple Myeloma

(Celgene) Feb 6, 2018 - Study met its primary endpoint demonstrating significant improvement in progression-free survival (PFS) with POMALYST®/IMNOVID® in combination with bortezomib and dexamethasone (PVd) compared with bortezomib and low-dose dexamethasone.

read corporate press release

Patients to Benefit From Myeloma Treatment Through CDF Deal

(NICE) Feb 7, 2018 - Up to 1,600 patients with multiple myeloma could benefit from a new oral pill after NICE recommends ixazomib, also known as Ninlaro, for use within the Cancer Drugs Fund (CDF).

read article

Bluebird CAR-T Still Top Celgene Priority After Juno Deal

(Reuters) Jan 25, 2018 - Celgene Corp said on Thursday that a pending $9 billion purchase of Juno Therapeutics in no way alters its focus on its partnership with Juno rival bluebird bio.

read article

Frontline Daratumumab Granted FDA's Priority Review for Multiple Myeloma

(Targeted Oncology) Jan 22, 2018 - Based on findings from the ALCYONE study, which were published in the New England Journal of Medicine and presented at the 2017 ASH Annual Meeting, the FDA has granted a priority review designation to daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

read article

U.S. Doctors Plan to Treat Cancer Patients Using CRISPR

(MIT Technology Review) Jan 17, 2018 - The first human test in the U.S. involving the gene-editing tool CRISPR could begin at any time and will employ the DNA cutting technique in a bid to battle deadly cancers.

read article

ASCO Updates Recommendations for Bone-Modifying Agents in Multiple Myeloma

(Journal Of Clinical Pathways) Jan 22, 2018 - The American Society of Clinical Oncology (ASCO) released a clinical practice guideline update on the role of bone-modifying agents in patients with active symptomatic multiple myeloma, published in the Journal of Clinical Oncology (online January 17, 2018; doi:10.1200/JCO.2017.76.6402).

read article

U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma

(Yahoo! Finance) Jan 19, 2018 - Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for the use of daratumumab (DARZALEX®) in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

read article

Phosplatin Therapeutics Announces First Cohort Enrolled in Phase I / II Trial of PT-112 in Relapsed/Refractory Multiple Myeloma, and Receipt of FDA Orphan Drug Designation

(Business Insider) Feb 7, 2018 - Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology drug development, announced today it has enrolled the first cohort of patients into its Phase I / II study of PT-112 as a single agent in relapsed or refractory multiple myeloma.

read article

Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000

(Forbes) Feb 8, 2018 - David Mitchell, 67, says he’s sure that Novartis’ Kymriah is a breakthrough medicine, and that he will need a similar medicine to treat his own blood cancer. He’s sure of something else, too: Novartis is charging too much.

read article

Cognitive Decline Prevalent Among Elderly Patients With Hematologic Cancers, Study Finds

(BWH) Mar 5, 2018 - A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning, a decline that may impact their survival, a new study by investigators at Dana-Farber Cancer Institute and Brigham and Women's Hospital indicates.

read press release

SELLAS Life Sciences’ Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting

( Mar 19, 2018 - SELLAS Life Sciences Group, Inc. today announced the presentation of open label Phase 2 clinical and immunological data for its lead cancer immunotherapeutic candidate, galinpepimut-S (GPS), in the treatment of high-risk multiple myeloma at the 44th Annual European Society for Blood and Marrow Transplantation (EBMT) Meeting.

read article

AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma

(Business Insider) Mar 21, 2018 - Abbie and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand and help manage multiple myeloma (MM), the second most common blood cancer.

read article

Oncologists Getting 6% of Drug Price Is 'Financial Conflict'

(Medscape Medical News) Mar 7, 2018 - "No one is immune from $ temptation.... We have a system that rewards oncologists and their chemotherapy offices with more $ for giving more expensive chemo. This has to change," said Vincent Rajkumar, MD, a professor of medicine and a hematologist/oncologist at the Mayo Clinic, Rochester, Minnesota.

read article (free registration required)

Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma

(Seattle Genetics) Mar 7, 2018 - Seattle Genetics, Inc. today announced dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for patients with relapsed or refractory multiple myeloma (MM).

read corporate press release

BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China

(Morningstar) Feb 27, 2018 - BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that REVLIMID® (lenalidomide) has been approved by the China Food and Drug Administration (CFDA) for the treatment of multiple myeloma (MM) in combination with dexamethasone in adult patients with previously untreated MM who are not eligible for transplant.

read article

Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations

(NASDAQ) Feb 28, 2018 - Actinium’s lead product candidate, Iomab-B, is currently being studied in a pivotal Phase 3 trial as a myeloablative conditioning agent prior to a bone marrow transplant.

read article

GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML

(Morningstar) Mar 5, 2018 - Primary endpoint for single pivotal clinical trial will be overall survival; top-line data expected Q4 2020.

read article

A Doctor Speaks, A Biotech Stock Tanks. What Happened At This Invite-Only Health Care Investor Conference?

(STAT Plus) Mar 21, 2018 - A prominent Boston oncologist is downplaying comments he made at an invitation-only event last week that quickly spread among investors and set off alarm bells about an experimental multiple myeloma cell therapy from Bluebird Bio and Celgene.

read article (paid subscription required)
Next Page